FDA Grants Priority Review to Tesaro’s Niraparib

Tesaro was granted Priority Review by the FDA for niraparib in ovarian cancer. Its PDUFA date is set for June 2017.

Niraparib is a PARP inhibitor being evaluated in patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, following response to platinum-based chemotherapy.